Table 3.
Peri-procedural drug therapy
| Drug type | Drug | All patients | Vessel diameters ≤2.50 mm | Vessel diameters >2.5 mm | p value small versus large vessel diameters |
|---|---|---|---|---|---|
| Antiplatelet therapy (APT) | Aspirin | 783 (100 %) | 205 (100.0 %) | 578 (100.0 %) | 0.009 |
| Clopidogrel | 663 (84.7 %) | 164 (80.0 %) | 499 (86.3 %) | ||
| Prasugrel | 78 (10.0 %) | 23 (11.2 %) | 55 (9.5 %) | ||
| Ticagrelor | 30 (3.8 %) | 16 (7.8 %) | 14 (2.4 %) | ||
| Ticlopidine | 2 (0.3 %) | 0 (0.0 %) | 2 (0.3 %) | ||
| GP IIb/IIIa inhibitors | 10 (1.3 %) | 2 (1.0 %) | 8 (1.4 %) | ||
| Oral anti-coagulation | None | 694 (88.6 %) | 188 (91.7 %) | 506 (87.5 %) | 0.106 |
| Vitamin K antagonist (VKA) | 74 (9.5 %) | 12 (5.9 %) | 62 (10.7 %) | ||
| New oral anticoagulation (NOAC) rivaroxaban | 15 (1.9 %) | 5 (2.4 %) | 10 (1.7 %) | ||
| Triple Therapy (OAC + DAPT) | OAC + Aspirin + Clopidogrel | 70 (8.9 %) | 14 (6.8 %) | 56 (9.7 %) | 0.451 |
| OAC + Aspirin + Prasugrel | 2 (0.3 %) | 0 (0.0 %) | 2 (0.3 %) | ||
| OAC + Aspirin + Ticagrelor | 1 (0.1 %) | 0 (0.0 %) | 1 (0.2 %) |
OAC oral anti-coagulation